| ID | 1118 |
| Name of the vaccine | Typbar TCV |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | From 6 months |
| Description of the vaccine | World’s first Typhoid conjugate vaccine. |
| Name of the manufacturer | Bharat Biotech |
| Name of the manufacturing country | India |
| Year of manufacture | 2013 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | Protective efficacy of 87% against typhoid fever. |
| Vaccine formulation | Turbid liquid |
| Dosage | Single dose of 0.5 mL and a booster dose may be given after 3 years. |
| Mechanism of action | T-cell dependent, induces Vi antibodies that neutralize Vi antigen. |
| Route of administration | Intramuscular |
| Indications | Long term protection against typhoid fever. |
| Export | Marketed by : Bharat Biotech International Ltd, India |
| Approval | WHO pre-qualified |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Pain at injection site, swelling, fever and headache. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf |
| Other name | NA |
| Additional Links | https://www.bharatbiotech.com/images/typbartcv/Typbar-TCV-Package-Insert.pdf
|